Contineum Therapeutics Prices Upsized $90 Million Class A Share Offering

BRIEF-Contineum Therapeutics Prices Upsized $90 Million Public Offering At $12.25 Per Share

Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering

Contineum Therapeutics Inc - Offering of 7.3 Mln Shares at $12.25 per Share

BUZZ-Contineum Therapeutics falls on planned $75 million share sale

Contineum Therapeutics Inc - Phase 2 Trial for Pipe-791 Expected to Be Completed in June 2028 - SEC Filing

Contineum Therapeutics Is Maintained at Outperform by Baird

Contineum price target lowered to $14 from $16 at Baird

Contineum Shares Fall After Phase 2 PIPE-307 Trial Fails to Meet Efficacy Goals in Multiple Sclerosis

Contineum Therapeutics Is Maintained at Outperform by RBC Capital

Contineum Therapeutics: Undervalued Potential in IPF with PIPE-791 Amidst PIPE-307 Setback

Contineum Therapeutics Inc : Jonestrading Cuts Target Price to $22 From $25

Contineum Therapeutics, Inc. Class A (CTNM) Gets a Buy from RBC Capital

Positive Outlook on Contineum Therapeutics Despite Setbacks, Driven by PIPE-791’s Potential in IPF

RBC Lowers Price Target on Contineum Therapeutics to $22 From $25, Keeps Outperform, Speculative Risk

Stocks to Watch: Contineum, Gap Inc., Geospace Technologies

Optimistic Buy Rating for Contineum Therapeutics Amid Promising PIPE-791 Developments

Contineum Therapeutics MS Treatment Fails to Meet Trial Endpoints

BRIEF-Contineum Therapeutics Reports Topline Data From Its Phase 2 Pipe-307 Vista Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis

Contineum Therapeutics Reports Phase 2 Trial Results